These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 31316178)

  • 1. LW-213, a newly synthesized flavonoid, induces G2/M phase arrest and apoptosis in chronic myeloid leukemia.
    Liu X; Hu P; Li H; Yu XX; Wang XY; Qing YJ; Wang ZY; Wang HZ; Zhu MY; Guo QL; Hui H
    Acta Pharmacol Sin; 2020 Feb; 41(2):249-259. PubMed ID: 31316178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel tubulin polymerization inhibitor, MPT0B206, downregulates Bcr-Abl expression and induces apoptosis in imatinib-sensitive and imatinib-resistant CML cells.
    Chen CW; Lee YL; Liou JP; Liu YH; Liu CW; Chen TY; Huang HM
    Apoptosis; 2016 Sep; 21(9):1008-18. PubMed ID: 27344662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-dose staurosporine selectively reverses BCR-ABL-independent IM resistance through PKC-α-mediated G2/M phase arrest in chronic myeloid leukaemia.
    Ma D; Wang P; Fang Q; Yu Z; Zhou Z; He Z; Wei D; Yu K; Lu T; Zhang Y; Wang J
    Artif Cells Nanomed Biotechnol; 2018; 46(sup3):S208-S216. PubMed ID: 30618318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MPT0B169, a New Antitubulin Agent, Inhibits Bcr-Abl Expression and Induces Mitochondrion-Mediated Apoptosis in Nonresistant and Imatinib-Resistant Chronic Myeloid Leukemia Cells.
    Wong SM; Liu FH; Lee YL; Huang HM
    PLoS One; 2016; 11(1):e0148093. PubMed ID: 26815740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Growth inhibition and differentiation of imatinib-resistant chronic myeloid leukemia cell induced by cell differentiation agent in vitro].
    Wang XD; Qiu L; Lu RZ; Chen LJ; Zhan ZM; Han BH; Zhang BL; Ma J
    Zhonghua Yi Xue Za Zhi; 2007 Dec; 87(48):3399-405. PubMed ID: 18476538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines.
    Xin P; Li C; Zheng Y; Peng Q; Xiao H; Huang Y; Zhu X
    Drug Des Devel Ther; 2017; 11():1115-1126. PubMed ID: 28435223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gambogic acid induces apoptosis in imatinib-resistant chronic myeloid leukemia cells via inducing proteasome inhibition and caspase-dependent Bcr-Abl downregulation.
    Shi X; Chen X; Li X; Lan X; Zhao C; Liu S; Huang H; Liu N; Liao S; Song W; Zhou P; Wang S; Xu L; Wang X; Dou QP; Liu J
    Clin Cancer Res; 2014 Jan; 20(1):151-63. PubMed ID: 24334603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Celecoxib inhibits proliferation and survival of chronic myelogeous leukemia (CML) cells via AMPK-dependent regulation of β-catenin and mTORC1/2.
    Riva B; De Dominici M; Gnemmi I; Mariani SA; Minassi A; Minieri V; Salomoni P; Canonico PL; Genazzani AA; Calabretta B; Condorelli F
    Oncotarget; 2016 Dec; 7(49):81555-81570. PubMed ID: 27835591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blockade of the interaction between Bcr-Abl and PTB1B by small molecule SBF-1 to overcome imatinib-resistance of chronic myeloid leukemia cells.
    Elgehama A; Chen W; Pang J; Mi S; Li J; Guo W; Wang X; Gao J; Yu B; Shen Y; Xu Q
    Cancer Lett; 2016 Mar; 372(1):82-8. PubMed ID: 26721204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A molecular and biophysical comparison of macromolecular changes in imatinib-sensitive and imatinib-resistant K562 cells exposed to ponatinib.
    Yandim MK; Ceylan C; Elmas E; Baran Y
    Tumour Biol; 2016 Feb; 37(2):2365-78. PubMed ID: 26373734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Idelalisib induces G1 arrest and apoptosis in chronic myeloid leukemia K562 cells.
    Chen Y; Zhou Q; Zhang L; Wang R; Jin M; Qiu Y; Kong D
    Oncol Rep; 2016 Dec; 36(6):3643-3650. PubMed ID: 27748929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 2-Hydroxypropyl-β-Cyclodextrin Acts as a Novel Anticancer Agent.
    Yokoo M; Kubota Y; Motoyama K; Higashi T; Taniyoshi M; Tokumaru H; Nishiyama R; Tabe Y; Mochinaga S; Sato A; Sueoka-Aragane N; Sueoka E; Arima H; Irie T; Kimura S
    PLoS One; 2015; 10(11):e0141946. PubMed ID: 26535909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CM363, a novel naphthoquinone derivative which acts as multikinase modulator and overcomes imatinib resistance in chronic myelogenous leukemia.
    Guerra B; Martín-Rodríguez P; Díaz-Chico JC; McNaughton-Smith G; Jiménez-Alonso S; Hueso-Falcón I; Montero JC; Blanco R; León J; Rodríguez-González G; Estévez-Braun A; Pandiella A; Díaz-Chico BN; Fernández-Pérez L
    Oncotarget; 2017 May; 8(18):29679-29698. PubMed ID: 27557509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Wogonin induces cell cycle arrest and erythroid differentiation in imatinib-resistant K562 cells and primary CML cells.
    Yang H; Hui H; Wang Q; Li H; Zhao K; Zhou Y; Zhu Y; Wang X; You Q; Guo Q; Lu N
    Oncotarget; 2014 Sep; 5(18):8188-201. PubMed ID: 25149543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pseudolaric acid B induces mitotic arrest and apoptosis in both imatinib-sensitive and -resistant chronic myeloid leukaemia cells.
    Jiang L; Wen C; He Q; Sun Y; Wang J; Lan X; Rohondia S; Dou QP; Shi X; Liu J
    Eur J Pharmacol; 2020 Jun; 876():173064. PubMed ID: 32179085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stellettin B induces apoptosis in human chronic myeloid leukemia cells via targeting PI3K and Stat5.
    Chen Y; Zhou Q; Zhang L; Zhong Y; Fan G; Zhang Z; Wang R; Jin M; Qiu Y; Kong D
    Oncotarget; 2017 Apr; 8(17):28906-28921. PubMed ID: 28423649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tetrandrine citrate eliminates imatinib-resistant chronic myeloid leukemia cells in vitro and in vivo by inhibiting Bcr-Abl/β-catenin axis.
    Xu XH; Gan YC; Xu GB; Chen T; Zhou H; Tang JF; Gu Y; Xu F; Xie YY; Zhao XY; Xu RZ
    J Zhejiang Univ Sci B; 2012 Nov; 13(11):867-74. PubMed ID: 23125079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytotoxic effect of 6-Shogaol in Imatinib sensitive and resistant K562 cells.
    Ozkan T; Hekmatshoar Y; Pamuk H; Ozcan M; Yaman G; Yagiz GC; Akdemir C; Sunguroglu A
    Mol Biol Rep; 2021 Feb; 48(2):1625-1631. PubMed ID: 33515349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib.
    Zhang GS; Liu DS; Dai CW; Li RJ
    Am J Hematol; 2006 Apr; 81(4):242-55. PubMed ID: 16550520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of imatinib-resistant K562 cell line displaying resistance mechanisms.
    Hekmatshoar Y; Ozkan T; Altinok Gunes B; Bozkurt S; Karadag A; Karabay AZ; Sunguroglu A
    Cell Mol Biol (Noisy-le-grand); 2018 May; 64(6):23-30. PubMed ID: 29808796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.